标题
Quantifying the impact of immunotherapy on RNA dynamics in cancer
作者
关键词
-
出版物
Journal for ImmunoTherapy of Cancer
Volume 11, Issue 11, Pages e007870
出版商
BMJ
发表日期
2023-11-01
DOI
10.1136/jitc-2023-007870
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- TLR5 agonists enhance anti-tumor immunity and overcome resistance to immune checkpoint therapy
- (2023) Caleb Gonzalez et al. Communications Biology
- Local γδ T cells: translating promise to practice in cancer immunotherapy
- (2023) Iva Zlatareva et al. BRITISH JOURNAL OF CANCER
- Genomic–transcriptomic evolution in lung cancer and metastasis
- (2023) Carlos Martínez-Ruiz et al. NATURE
- Immune-checkpoint inhibitors: long-term implications of toxicity
- (2022) Douglas B. Johnson et al. Nature Reviews Clinical Oncology
- Toll-like receptor agonist combinations augment mouse T-cell anti-tumor immunity via IL-12- and interferon ß-mediated suppression of immune checkpoint receptor expression
- (2022) Donghwan Jeon et al. OncoImmunology
- IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer
- (2022) Olga S. Blomberg et al. CANCER CELL
- Novel immune-related genes in the tumor microenvironment with prognostic value in breast cancer
- (2021) Wen Tan et al. BMC CANCER
- Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
- (2021) Kevin Litchfield et al. CELL
- Knocking out alpha-synuclein in melanoma cells dysregulates cellular iron metabolism and suppresses tumor growth
- (2021) Sahar Shekoohi et al. Scientific Reports
- Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers
- (2021) Justina X. Caushi et al. NATURE
- A TLR4 agonist improves immune checkpoint blockade treatment by increasing the ratio of effector to regulatory cells within the tumor microenvironment
- (2021) A. Farias et al. Scientific Reports
- High Expression of SLC16A1 as a Biomarker to Predict Poor Prognosis of Urological Cancers
- (2021) Ling Zhang et al. Frontiers in Oncology
- Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma
- (2021) Lewis Au et al. CANCER CELL
- SOX10 Regulates Melanoma Immunogenicity through an IRF4–IRF1 Axis
- (2021) Satoru Yokoyama et al. CANCER RESEARCH
- Improved prediction of immune checkpoint blockade efficacy across multiple cancer types
- (2021) Diego Chowell et al. NATURE BIOTECHNOLOGY
- Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape
- (2021) Yoshiko Takeuchi et al. Science Immunology
- MICA and KLRK1 genes and their impact in cervical intraepithelial neoplasia development in the southern Brazilian population
- (2020) Renate von Linsingen et al. HUMAN IMMUNOLOGY
- Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma
- (2020) Benjamin P. Fairfax et al. NATURE MEDICINE
- HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients
- (2020) J.H. Shim et al. ANNALS OF ONCOLOGY
- Super-enhancer acquisition drives oncogene expression in triple negative breast cancer
- (2020) Ryan Raisner et al. PLoS One
- Peripheral cytokine levels as predictive biomarkers of benefit from immune checkpoint inhibitors in cancer therapy
- (2020) Shoujian Ji et al. BIOMEDICINE & PHARMACOTHERAPY
- Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
- (2020) Nick van Dijk et al. NATURE MEDICINE
- Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines
- (2020) Ji-Eun Park et al. Journal for ImmunoTherapy of Cancer
- Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma
- (2020) Jeffrey C Thompson et al. Journal for ImmunoTherapy of Cancer
- Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
- (2019) Sarabjot Pabla et al. Journal for ImmunoTherapy of Cancer
- Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy
- (2019) Melvyn T. Chow et al. IMMUNITY
- Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
- (2019) Leonie Voorwerk et al. NATURE MEDICINE
- Clonal replacement of tumor-specific T cells following PD-1 blockade
- (2019) Kathryn E. Yost et al. NATURE MEDICINE
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- A clonal expression biomarker associates with lung cancer mortality
- (2019) Dhruva Biswas et al. NATURE MEDICINE
- Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
- (2019) Thomas Powles et al. NATURE MEDICINE
- An innate-like Vδ1+ γδ T cell compartment in the human breast is associated with remission in triple-negative breast cancer
- (2019) Yin Wu et al. Science Translational Medicine
- Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
- (2019) David Liu et al. NATURE MEDICINE
- Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
- (2018) Seung Tae Kim et al. NATURE MEDICINE
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- (2018) David F. McDermott et al. NATURE MEDICINE
- Immunological differences between primary and metastatic breast cancer
- (2018) B Szekely et al. ANNALS OF ONCOLOGY
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
- (2018) Peng Jiang et al. NATURE MEDICINE
- Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
- (2018) Noam Auslander et al. NATURE MEDICINE
- EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer
- (2018) Li Wang et al. Nature Communications
- Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
- (2018) Leisha A. Emens et al. JAMA Oncology
- Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
- (2017) Alexander C. Huang et al. NATURE
- Resistance to checkpoint blockade therapy through inactivation of antigen presentation
- (2017) Moshe Sade-Feldman et al. Nature Communications
- Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
- (2017) Scott Gettinger et al. Cancer Discovery
- Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis
- (2017) Alexandra Snyder et al. PLOS MEDICINE
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
- (2016) Valsamo Anagnostou et al. Cancer Discovery
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
- (2015) Michael S. Rooney et al. CELL
- TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data
- (2015) Antonio Colaprico et al. NUCLEIC ACIDS RESEARCH
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients
- (2014) E. Cha et al. Science Translational Medicine
- 12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?
- (2012) Jane L. Messina et al. Scientific Reports
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started